By REUTERS
The formal investigation poses a new challenge to the drugmaker GlaxoSmithKline, which already faces claims of bribery in China and four other countries.
Published: May 28, 2014 at 4:00AM
from NYT Business Day http://ift.tt/SNm1mn
via IFTTT
from WordPress http://ift.tt/RzuVCL
No comments:
Post a Comment